Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Jenburkt Pharmaceuticals Limited

NSE: JENBURPHPharmaceuticals

Share price

₹954.20

+7.05% close of 8 Oct 2026

Market cap ₹382 CrP/E 11.6

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 5 Oct 2026, the close above is 8 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

65

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹382 Cr

P/E ratio

11.6

P/B ratio

2.1

ROCE

27.0%

ROE

19.0%

Dividend yield

2.3%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹1,275.8552-week low ₹891.40

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 9.1% over the past year, and 8.5% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 22.5% to 23.7% over the last four years.

Whether it grew faster than its sector

It grew 8.5% a year against a sector median of 13.1% — 4.5 percentage points slower.

Room to re-rate, or risk of de-rating

At 11.6× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 68.6×, across 4 companies. It is against its own five-year median of 12.9×, the 24th percentile of its own range.

Whether growth justifies the valuation

Priced at 0.8 times its growth rate, on earnings growth of 15%.

Profit growthPrice per ₹1 profitPer 1% growth
Jenburkt Pharmaceuticals Limited — this one15%/yr11.6×₹0.78
Emcure Pharmaceuticals Limited21%/yr34.2×₹1.6
Wockhardt Limited43%/yr82.4×₹1.9
Sai Life Sciences Limited227%/yr85.9×—
Neuland Laboratories Limited30%/yr54.7×₹1.8
Piramal Pharma Limited-31%/yr——

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 17 of 130 on returns, 84 of 127 on growth, 38 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 27% on capital, ahead of 87% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹89 crore of cash from the business, spent ₹40 crore on plant and equipment, and returned ₹51 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 74 arrived as cash. Its cash comes back more slowly than it used to: it went from being waiting 16 days for its cash to waiting 41 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

6 of 7 checks clear · 86%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 6 Aug 2026 · Standalone · Unaudited

Revenue

₹36 Cr

Revenue vs last year

-0.1%

Revenue vs last quarter

-20.4%

Net profit

₹6 Cr

Profit vs last year

-24.4%

Profit vs last quarter

-45.8%

Net margin

16.6%

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹382 Cr
Prev close
₹954.20
52w High
₹1,321
52w Low
₹864
Enterprise value
₹423 Cr
Beta
0.9
Price CAGR 1y
-15.0%
Price CAGR 3y
10.0%
Price CAGR 5y
13.0%
Price CAGR 10y
10.0%

Ratios

Return on assets
15.6%
PEG ratio
0.8
P/E ratio
11.6
P/B ratio
2.1
EV / EBITDA
9.6
Industry P/E
38.0
ROCE
27.0%
ROCE 5y average
26.6%
ROE
19.0%
Debt / Equity
0.0
Interest coverage
—
Dividend yield
2.3%
ROE 3y average
20.0%
ROE last year
20.0%

Annual P&L

Annual revenue
₹169 Cr
Annual profit
₹35 Cr
Operating margin
26.0%
Net profit margin
20.7%
EBITDA margin
26.0%
Sales growth 3y
7.2%
Sales growth 5y
9.2%
Profit growth 3y
15.0%
Profit growth 5y
18.0%
EPS
₹78.7
Sales growth TTM
9.0%
Profit growth TTM
10.0%
Dividend payout
26.0%

Quarter P&L

Sales latest quarter
₹36 Cr
Profit latest quarter
₹6 Cr
YoY quarterly sales growth
-0.1%
YoY quarterly profit growth
-24.4%
OPM latest quarter
17.0%

Balance Sheet

Book Value
₹493
Face Value
₹10.0
Total debt
₹2 Cr
Total cash
—
Borrowings
₹2 Cr
Reserves / Equity
48.3

Cash Flow

Operating cash flow
₹27 Cr
Free cash flow
₹13 Cr
FCF yield
3.4%
Net cash flow
-₹2 Cr

Shareholding

Promoter holding
46.6%
FII holding
0.0%
DII holding
0.1%
Public holding
53.3%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,784.7034.04,28,2090.892,901.26.015,299.910.520.5
Divi's Lab.9,158.3081.62,43,1240.32902.065.53,080.027.822.0
Torrent Pharma.4,746.6581.01,80,5470.80566.05.84,921.054.915.2
Zydus Lifesci.1,141.0023.41,13,8150.09990.2-35.18,017.022.021.1
Cipla1,333.7030.11,07,7460.98785.6-39.27,119.32.315.5
Laurus Labs1,963.0597.01,06,0660.10362.1125.52,026.329.117.8
Mankind Pharma2,481.6048.11,02,5010.04574.129.64,030.612.913.5
Jenburkt Pharma892.0011.03942.325.9-24.435.5-0.126.9
Median413.5034.32,1540.0613.229.6160.318.614.9

Competes with: Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Standalone · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales29383639334137413646434536
Expenses22292829233028302732363029
Material Cost2.32
Change in Inventories-1.47
Purchases of Stock-in-Trade5.48
Employee Cost13
Other Expenses10
Operating Profit6.969.107.199.859.28118.82118.95137.43146.03
OPM %24242025292824262529173217
Other Income1.041.101.351.191.411.851.581.882.062.081.820.401.51
Exceptional items (within Other Income)0
Interest0.070.070.070.060.110.120.110.110.110.110.120.130.13
Depreciation0.500.590.630.620.520.640.780.790.720.740.830.810.64
Profit before tax7.439.547.841010139.511210148.30146.77
Tax %28233124262332282329292113
Net Profit5.377.325.407.887.429.606.518.547.79105.93115.89
EPS in Rs12171218172215191823132513

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Standalone · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales8594103115123119109124137142152169169
Expenses7077849198998997106109111125128
Operating Profit15162024252020273033404441
OPM %18181921201718222223272624
Other Income2333344555766
Interest0000010000000
Depreciation3222122222333
Profit before tax14172025272122303335444743
Tax %333634322630242525262725
Net Profit10111417201516222526323533
EPS in Rs21232938433236495659737974
Dividend Payout %303128242425282526262526

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
6%
5 years
9%
3 years
7%
TTM
9%

Compounded profit growth

10 years
13%
5 years
18%
3 years
15%
TTM
10%

Stock price CAGR

10 years
10%
5 years
13%
3 years
10%
1 year
-15%

Return on equity

10 years
21%
5 years
20%
3 years
20%
Last year
20%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital555555554444
Reserves29365057737594113118141167193
Borrowings756073573042
Other Liabilities211216161821171816191926
Total Liabilities61587677103104120143141164195225
Fixed Assets121211101012111110101519
CWIP00001000114046
Investments0125547811172127
Other Assets494564628788103123119136120132
Total Assets61587677103104120143141164195225

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity98101613151991782827
Cash from Investing Activity1-0-101-11-3-19-13-1-17-19
Cash from Financing Activity1-51-18-2-11-1-6-21-7-8-9
Net Cash Flow1121-101-03-103-2
Free Cash Flow8510161111187156813

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days322332406855474545505053
Inventory Days10710912873991209211592103109154
Days Payable5444724466585683677510091
Cash Conversion Cycle858889691011178377707859115
Working Capital Days-11610253532171631363141
ROCE %424039423726242627262727

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Standalone · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters474747474747474747474747
FIIs1.3800000000000
DIIs000000.120.120.120.120.120.120.12
Public515353535353535353535353
No. of Shareholders5,8726,0216,3166,4196,6286,9016,9876,7126,8557,1636,9997,103

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -11.1% (₹1,073.55 → ₹954.20)Brick size ₹44.45 (fixed)Bricks 18
₹900₹1,000₹1,100₹1,200₹954Dec '25May '26Sep '26
Price moved up one brickPrice moved down one brickLast close ₹954.20 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

News

News and filings about Jenburkt Pharmaceuticals Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE354A01013

News impact

Big market events that reach Jenburkt Pharmaceuticals Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

28 Aug 2026unspecified₹20.7

Documents

Annual reports, results presentations and earnings calls, straight from the source.

No documents on record yet.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.